Thursday, August 31, 2017

Drugs targeting the beta2-adrenoreceptor linked to Parkinson's disease

Researchers want to prevent alpha-synuclein from accumulating in the brain. To do so, the team searched for drugs that turn down alpha-synuclein production. They then tested the drugs in mice and stem cells and studied in data from the health records of millions of people living in Norway. The results of their efforts, point to a new drug development path for PD.
https://www.sciencedaily.com/releases/2017/08/170831141255.htm